First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

CanSinoBIO offered tens of millions of COVID-19 vaccine...

Newsdeck

Newsdeck

CanSinoBIO offered tens of millions of COVID-19 vaccine doses to COVAX -exec

Vaccine research has accelerated on an unprecedented, although welcomed, basis, with over 200 vaccine candidates in various stages of clinical research. (Photo: EPA-EFE/ANATOLY MALTSEV)
By Reuters
25 Mar 2021 0

BEIJING, March 25 (Reuters) - China's CanSino Biologics Inc (CanSinoBIO) has proposed supplying "tens of million of doses" of its single-dose COVID-19 vaccine to global vaccine sharing scheme COVAX, a senior company executive said.

China has four locally developed COVID-19 vaccines approved for public use and pledged earlier to supply 10 million doses to COVAX without specifying the time frame of delivery. CanSinoBIO, Sinovac Biotech Ltd and China National Pharmaceutical Group Co Ltd (Sinopharm) have applied to join the initiative.

Pierre Morgon, senior vice president at CanSinoBIO, said the firm made the proposal in December to supply vaccines between late 2021 and the end of 2022.

“We are happy to go beyond 2022 if there was still an expectation to do so,” he told Reuters in an interview, adding it made its offer at a middle single digit U.S. dollar per dose.

“I can’t tell you the exact number, but I can tell you, it’s a very competitive price,” Morgon said.

The offering to COVAX, which is backed by the World Health Organization (WHO), is the lowest price in the “tiered pricing mechanism” that CanSinoBIO uses in markets outside China, where richer countries are subject to higher prices.

There is a more than threefold factor difference between the highest price offer and the lowest, Morgon said.

Its vaccine, jointly developed with China’s military research institute, is approved for use in China, Pakistan, Hungary and Mexico.

The three Chinese vaccine makers are still awaiting decisions on whether they can be included in the WHO’s Emergency Use Listing, a prerequisite to join COVAX. (Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Christopher Cushing)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]

Gallery

Please peer review 3 community comments before your comment can be posted